By Sysy Morales
Many patients with type 2 diabetes are at risk for or have heart disease. Canagliflozin, which is marketed as Invokana, is in the class of drugs known as sodium-glucose cotransporter 2 inhibitors which lower blood sugar but also blood pressure, body weight, and albuminuria in people with diabetes, possibly providing a more comprehensive treatment than some other diabetes medications.
Researchers with the CANVAS Program used data from two trials that had a total of 10,142 participants with type 2 diabetes and a high cardiovascular risk. The study abstract states that the participants involved in each trial were randomly given either canagliflozin or a placebo for a mean of 188 weeks.
The mean age of the 2 trial participants was 63 years, 35.8% were women, the mean duration of their diabetes was 13.5 years, and 65.6% of the participants had a history of heart disease.
Can Canagliflozin Help Those With Type 2 and Heart Disease?
The main thing they looked at “was a composite of death from cardiovascular causes, nonfatal [heart attack], or nonfatal stroke,” write the study authors.
The study results showed that canagliflozin might help slow progression of alubinuria.
Canagliflozin was tied to an increased risk for amputation which were observed mostly involving toes or metatarsals.
The researchers concluded that the patients taking canagliflozin had a lower risk of cardiovascular events than those who took placebos. They did, however have a higher risk for amputation.